Analystreport

Trillium Therapeutics Inc. (NASDAQ: TRIL) had its price target raised by analysts at HC Wainwright from $16.50 to $22.00. They now have a "buy" rating on the stock.

Trillium Therapeutics Inc. - Common Shares  (TRIL) 
Last trillium therapeutics inc. - common shares earnings: 5/13 07:00 am Check Earnings Report